Fresh analysis suggests that people who discontinue popular GLP-1 drugs like semaglutide or tirzepatide can put back on shed pounds at a significantly accelerated pace than those who end conventional lifestyle regimens.
Research printed in a prominent health publication shows that while obese people often shed substantial amounts of their body weight while on the medication, the mass is regained at an estimated rate of nearly a kilo each month once they quit.
"Individuals using these treatments should be cognizant of the risk of fast weight regain when the therapy ends," cautioned researcher Dr. Susan Jebb.
Such speed of recovery means a reversion to starting weight within about 18 months.
Weighing Therapies
The study, which looked at 37 of trials involving over 9,000 of patients, compared the outcomes of GLP-1 agonists with conventional dieting.
Scientists emphasize that people who shed pounds through diet and exercise usually experience a less rapid creep back—perhaps 0.1 kg a month—once they finish.
The Reason for the Fast Regain
Experts believe the mode of action of the drugs explains the accelerated rebound.
The injections imitate a natural hormone called glucagon-like peptide-1, which moderates appetite.
"Sustained high doses of the hormone concentrations several times higher than normal may cause the system to generate a reduced amount of its endogenous GLP-1, and may also diminish sensitivity to its actions," explained Dr. Adam Collins, a nutrition specialist.
"Stopping of this medication results in appetite is unsuppressed, making overeating far more likely."
An Ongoing Issue?
The NHS advise the jabs for people with obesity-related medical conditions, accompanied by recommended lifestyle changes.
A number of clinicians say that, given the significant potential of relapse, the therapy should be considered long-term.
This opinion is echoed by drug manufacturers, who state that the results "highlight the persistent nature of excess weight," comparing it to managing conditions like diabetes.
Patient Testimonies
Users who have come off the jabs describe a intense return of cravings.
"It felt as if something that goes on and you're instantly starving," recalled a patient.
This challenge is compounded if users have not established permanent dietary or behavioural changes during therapy.
Significant Adoption
Survey data show that a significant number of people in the UK have tried weight-loss jabs in the last 12 months, with interest continuing to grow.
- Adoption is more common among females than males.
- The 40s and 50s age group shows the highest level of interest.
- Many access the medications through private healthcare rather than public health services.
Finally, researchers emphasize that while these medications are powerful agents for weight loss, they are not a permanent fix and maintained weight loss likely depends on ongoing behavioural changes.
